Enhanced triacylglycerol catabolism by carboxylesterase 1 promotes aggressive colorectal carcinoma
- J Clin Invest. 2021 Jun 1;131(11):e137845. doi: 10.1172/JCI137845.
- 1. Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.
- 2. Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L'Aquila, L'Aquila, Italy.
- 3. Department of Chemistry, Biology and Biotechnology, University of Perugia, Perugia, Italy.
- 4. Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom.
- 5. Singapore Institute for Clinical Sciences (SICS), and.
- 6. Institute of Molecular and Cell Biology (IMCB), Agency for Science Technology and Research (A*STAR), Singapore.
- 7. Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
- 8. Department of Medical, Oral, and Biotechnological Sciences, "G. D'Annunzio" University of Chieti-Pescara, Chieti, Italy.
- 9. Genome Institute of Singapore, Singapore.
- 10. Metabolon, Inc., Morrisville, North Carolina, USA.
The ability to adapt to low-nutrient microenvironments is essential for tumor cell survival and progression in solid cancers, such as colorectal carcinoma (CRC). Signaling by the NF-κB transcription factor pathway associates with advanced disease stages and shorter survival in patients with CRC. NF-κB has been shown to drive tumor-promoting inflammation, Cancer cell survival, and intestinal epithelial cell (IEC) dedifferentiation in mouse models of CRC. However, whether NF-κB affects the metabolic adaptations that fuel aggressive disease in patients with CRC is unknown. Here, we identified carboxylesterase 1 (CES1) as an essential NF-κB-regulated Lipase linking obesity-associated inflammation with fat metabolism and adaptation to energy stress in aggressive CRC. CES1 promoted CRC cell survival via cell-autonomous mechanisms that fuel fatty acid oxidation (FAO) and prevent the toxic build-up of triacylglycerols. We found that elevated CES1 expression correlated with worse outcomes in overweight patients with CRC. Accordingly, NF-κB drove CES1 expression in CRC consensus molecular subtype 4 (CMS4), which is associated with obesity, stemness, and inflammation. CES1 was also upregulated by gene amplifications of its transcriptional regulator HNF4A in CMS2 tumors, reinforcing its clinical relevance as a driver of CRC. This subtype-based distribution and unfavorable prognostic correlation distinguished CES1 from Other intracellular triacylglycerol lipases and suggest CES1 could provide a route to treat aggressive CRC.
-
Cat. No.Product NameDescriptionTargetResearch Area